Skip to main content
. 2016 Apr 12;214(2):216–225. doi: 10.1093/infdis/jiw146

Table 2.

Multivariable Linear Regression Model for CD4+ and CD8+ T-Cell Senescence

Variable HIV-Infected ART Recipients
Uninfected Controls
B (95% CI) Beta P Value B (95% CI) Beta P Value
CD4+CD27-CD28-
 Age 0.14 (−.05–.34) 0.15 .15 0.11 (−.08–.30) 0.11 .24
 CD8+ T-cell count 0.001 (−.003–.006) 0.07 .50 0.013 (.007–.019) 0.42 1.7 × 10−5
 CD4+CD38+HLA-DR+ 1.82 (.39–3.24) 0.26 .013 1.11 (.65–2.86) 0.12 .21
 CMV antibody titer 0.012 (−.018–.042) 0.081 .43 0.052 (.007–.096) 0.21 .022
CD4+CD57+
 Age 0.112 (−.093–.32) 0.11 .28 0.065 (−0.17–.30) 0.054 .57
 CD8+ T-cell count 0.001 (−.003–.006) 0.060 .53 0.013 (.006–.020) 0.35 .0006
 CD4+CD38+HLA-DR+ 2.95 (1.43–4.47) 0.39 .0002 2.22 (.051–4.39) 0.20 .045
CD8+CD27-CD28-
 Age 0.58 (.18–.98) 0.27 .005 0.53 (.078–.99) 0.21 .022
 CD4+ T-cell count −0.015 (−.027 to −.003) −0.24 .015 −0.004 (−.016–.008) −0.064 .51
 CD8+ T-cell count 0.014 (.004–.024) 0.28 .005 0.03 (.02–.05) 0.44 2.8 × 10−5
 CMV antibody titer 0.06 (−.005–.12) 0.17 .07 0.12 (.01–.23) 0.2 .03
 CD8+CD38+HLA-DR+ 1.04 (.27–1.81) 0.25 .009 0.34 (−.63–1.31) 0.07 .48
CD8+CD57+
 Age 0.43 (.045–.82) 0.2 .03 0.33 (−.13–.79) 0.138 .16
 CD4+ T-cell count −0.020 (−.032 to −.008) −0.33 .001 −0.003 (−.015–.009) −0.050 .63
 CD8+ T-cell count 0.014 (.005–.023) 0.29 .004 0.026 (.011–.041) 0.36 .001
 CD8+CD38+HLA-DR+ 1.46 (.73–2.20) 0.37 .0002 0.56 (−.42–1.54) 0.12 .26

Multivariate linear regression models included parameters selected by univariable linear regression analysis (age, CD4+ T-cell count, CD8+ T-cell count, ratio of CD4+ to CD8+ T cells, CMV high-avidity antibody titer, CMV antibody titer, activated CD4+ and CD8+ T cells, CD4+PD-1+ cells, and Treg percentage). Using a backward approach and optimization by hand, models were minimized to include only the most significant predictors.

Abbreviations: ART, antiretroviral therapy; CI, confidence interval; CMV, cytomegalovirus; HIV, human immunodeficiency virus; Treg, regulatory T cell.